About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Therapeutic Advances in Hematology
›
top-articles
Therapeutic Advances in Hematology
2.9
(top 20%)
impact factor
511
(top 50%)
papers
7.9K
(top 20%)
citations
42
(top 20%)
h
-index
3.0
(top 20%)
extended IF
520
all documents
8.6K
doc citations
64
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Myeloid sarcoma: current approach and therapeutic options
Therapeutic Advances in Hematology
2011
191
2
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Therapeutic Advances in Hematology
2013
172
3
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Therapeutic Advances in Hematology
2019
160
4
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Therapeutic Advances in Hematology
2014
151
5
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence
Therapeutic Advances in Hematology
2015
141
6
Treatment and management of graft-
versus
-host disease: improving response and survival
Therapeutic Advances in Hematology
2013
140
7
Management of imatinib-resistant patients with chronic myeloid leukemia
Therapeutic Advances in Hematology
2013
108
8
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Therapeutic Advances in Hematology
2011
104
9
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Therapeutic Advances in Hematology
2019
93
10
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Therapeutic Advances in Hematology
2012
90
11
New and emerging therapies for acute and chronic graft
versus
host disease
Therapeutic Advances in Hematology
2018
90
12
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Therapeutic Advances in Hematology
2019
90
13
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)
Therapeutic Advances in Hematology
2015
89
14
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Therapeutic Advances in Hematology
2013
85
15
Practical aspects of extended half-life products for the treatment of haemophilia
Therapeutic Advances in Hematology
2018
85
16
JAK2
allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
Therapeutic Advances in Hematology
2011
82
17
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
Therapeutic Advances in Hematology
2015
82
18
Gene therapy for hemophilia: what does the future hold?
Therapeutic Advances in Hematology
2018
79
19
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy
Therapeutic Advances in Hematology
2013
76
20
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Therapeutic Advances in Hematology
2019
71
21
Genetic predispositions to childhood leukemia
Therapeutic Advances in Hematology
2013
68
22
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies
Therapeutic Advances in Hematology
2016
66
23
Novel insights into the treatment of complement-mediated hemolytic anemias
Therapeutic Advances in Hematology
2019
65
24
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
Therapeutic Advances in Hematology
2019
65
25
Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions
Therapeutic Advances in Hematology
2013
61
26
Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Therapeutic Advances in Hematology
2014
57
27
Invasive fungal infections in acute leukemia
Therapeutic Advances in Hematology
2011
56
28
Recognizing familial myeloid leukemia in adults
Therapeutic Advances in Hematology
2013
55
29
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Therapeutic Advances in Hematology
2016
54
30
Extracorporeal photopheresis in the treatment of graft-
versus
-host disease: evidence and opinion
Therapeutic Advances in Hematology
2013
53
31
Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
Therapeutic Advances in Hematology
2018
53
32
Targeting the leukemia–stroma interaction in acute myeloid leukemia: rationale and latest evidence
Therapeutic Advances in Hematology
2016
52
33
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Therapeutic Advances in Hematology
2019
52
34
Ovarian vein thrombosis in the nonpregnant woman: an overlooked diagnosis
Therapeutic Advances in Hematology
2012
51
35
Current and emerging factor VIII replacement products for hemophilia A
Therapeutic Advances in Hematology
2017
51
36
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians
Therapeutic Advances in Hematology
2012
50
37
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Therapeutic Advances in Hematology
2018
50
38
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
Therapeutic Advances in Hematology
2019
50
39
Inherited predisposition to myeloproliferative neoplasms
Therapeutic Advances in Hematology
2013
49
40
Novel agents for the treatment of childhood acute leukemia
Therapeutic Advances in Hematology
2015
49
41
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Therapeutic Advances in Hematology
2016
47
42
Immunotherapy in myeloma: how far have we come?
Therapeutic Advances in Hematology
2019
47
43
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Therapeutic Advances in Hematology
2015
45
44
Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians
Therapeutic Advances in Hematology
2015
43
45
Azacitidine in the management of patients with myelodysplastic syndromes
Therapeutic Advances in Hematology
2012
42
46
Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile
Therapeutic Advances in Hematology
2012
42
47
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies
Therapeutic Advances in Hematology
2014
42
48
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Therapeutic Advances in Hematology
2017
42
49
Update on the role of lenalidomide in patients with multiple myeloma
Therapeutic Advances in Hematology
2018
42
50
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
Therapeutic Advances in Hematology
2019
42
site/software ©
exaly
; All materials licenced under
CC by-SA
.